LAWRENCE, Mass., May 24, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
Jefferies Healthcare Conference
Friday, June 10, 2016
1:30 p.m. ET
William Blair Growth Stock Conference
Tuesday, June 14, 2016
8:50 a.m. C.S.T.
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage has also established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's website at http://www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Mr. Burbank's plans to present at these conferences. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Kristen K. Sheppard, Esq.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-announces-second-quarter-2016-investor-conference-schedule-300273255.html
SOURCE NxStage Medical, Inc.